CAPR — Capricor Therapeutics, Inc. stock price, charts and financials

QT37Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
4.20
+0.35+9.09%
OverviewShort InterestFilings
CAPRQT37Capricor Therapeutics, Inc.·NASDAQ
4.20+9.09%
Analyst
Up 9.1% — Jones Trading downgraded to Hold.
High confidence
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
IOVA+6.14%$4.32FTRE-1.20%$18.94SLS+12.09%$11.22URGN+0.92%$38.59MESO+2.12%$14.47TSHA-1.37%$5.78TYRA+0.50%$32.04AUPH-2.08%$14.57
Snapshot
Index-P/E-EPS (ttm)-1.20Insider Own47.74%Shs Outstand57.91MPerf Week-80.46%
Market Cap222.96MForward P/E-EPS next Y-0.73Insider Trans-1.24%Shs Float48.55MPerf Month-83.31%
Enterprise Value138.66MPEG0.04EPS next Q-Inst Own-Short Float32.09%Perf Quarter-88.53%
Income-115.54MP/S0.00EPS this Y53.43%Inst Trans-Short Ratio12.87Perf Half Y-82.97%
Sales22.00MP/B0.79EPS next Y-30.02%ROA-35.12%Short Interest15.58MPerf YTD-86.66%
Book/sh-P/C-EPS next 5Y-ROE-59.27%52W High44.03 -90.46%Perf Year-52.93%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-40.00%52W Low3.23 30.07%Perf 3Y-13.29%
Dividend Est.-EV/EBITDA0.16Sales past 3/5Y-Gross Margin0.00%Volatility14.40% 8.53%Perf 5Y-20.78%
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-4.35%Oper. Margin0.00%ATR (14)2.18Perf 10Y-90.83%
Dividend Ex-Date-Quick Ratio8.42Sales Y/Y TTM0.00%Profit Margin0.00%RSI (14)11.37Recom2.40
Dividend Gr. 3/5Y-Current Ratio8.42EPS Q/Q-11.32%SMA20-77.15%Beta0.42Target Price5.83
Payout0.00%Debt/Eq0.08Sales Q/Q-SMA50-83.36%Rel Volume2.83Prev Close3.85
Employees231LT Debt/Eq0.05EarningsAug 11SMA200-83.47%Avg Volume2.57MPrice4.20
IPO DateFeb 13, 2007Option/ShortYes / YesEPS/Sales Surpr.-16.26% -Net Debt/EBITDA-0.09Volume7,262,843Change9.09%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-31-26DowngradeJones TradingBuy → Hold
Jul-30-26DowngradeCantor FitzgeraldOverweight → Neutral$3.50
Jul-30-26DowngradeHC Wainwright & Co.Buy → Neutral
Jul-30-26DowngradePiper SandlerOverweight → Neutral
Jul-28-26ReiteratedIndustrial Alliance Securities$7.00
Jul-27-26ReiteratedRoth CapitalBuy$7.00
May-15-26ReiteratedRoth CapitalBuy
Mar-13-26ReiteratedCantor FitzgeraldOverweight
Dec-15-25ReiteratedUBS
Dec-10-25ReiteratedPiper SandlerOverweight
Latest News
Today
Today05:45PM
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuitprnewswire.com
04:02PM
Kaplan Fox & Kilsheimer LLP Alerts Capricor Therapeutics, Inc. (CAPR) Investors to a Securities Class Action Deadline on September 28, 2026newsfilecorp.com
04:02PM
CAPR INVESTOR ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Capricor Class Action Lawsuitprnewswire.com
03:04PM
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadlinenewsfilecorp.com
02:55PM
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harmglobenewswire.com
06:36AM
CAPR Investigation Notice: Capricor Therapeutics Hit with Securities Fraud Investigation over Clinical Data Misrepresentations – Investors Urged to Contact BFA Lawglobenewswire.com
01:00AM
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPRprnewswire.com
Aug-01-26
Aug-01-2603:11PM
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Lawbusinesswire.com
Jul-31-26
Jul-31-2604:21PM
CAPR INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Capricor Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firmglobenewswire.com
11:00AM
CAPR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Capricor (CAPR)gurufocus.com
10:00AM
Law Offices of Howard G. Smith Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders To Inquire About Securities Fraud Class Actiongurufocus.com
09:00AM
CAPR INVESTIGATION: Block & Leviton Seeks to Speak With Capricor Therapeutics Investorsnewsfilecorp.com
06:46AM
$CAPR Securities: Suffer Losses on Your Capricor Therapeutics Investment? BFA Law Notifies Investors of the Securities Fraud Lawsuit to Recover Lossesglobenewswire.com
02:00AM
CAPR CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Capricor Therapeutics, Inc.businesswire.com
Jul-30-26
Jul-30-2610:00PM
CAPR CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit on Behalf of Capricor Therapeutics, Inc.gurufocus.com
Company

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue220222530012
Cost of Goods Sold Incl. D&A5105036220050
Gross Profit-280-28-11-1900-42
Selling, General and Administrative Excl. Other14231513108645
Research and Development5184503622148512
Other Operating Expense-511-50-36-22-10-50
Operating Income-43-108-43-24-30-21-14-8-15
Interest Expense030000000
Unusual Expense
—————————
Non-Operating Income (Expense)262211000
Net Income Before Taxes-41-105-40-22-29-20-14-8-15
Income Taxes
000000000
Consolidated Net Income-41-105-40-22-29-20-14-8-15
Net Income From Continuing Operations-41-105-40-22-29-20-14-8-15
Net Income-41-105-40-22-29-20-14-8-15
EPS (Recurring)-1.20-2.26-1.15-0.83-1.18-0.87-0.88-2.06-5.17
EPS (Basic, Before Extraordinaries)-1.20-2.26-1.15-0.83-1.18-0.87-0.88-2.06-5.17
EPS (Diluted)-1.20-2.26-1.15-0.83-1.18-0.87-0.88-2.06-5.17
EBITDA-39-100-39-21-28-20-14-8-15
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio6.68—21.955.2832.17——5.126.15
Gross Margin-127.27—-127.27-44.00-633.33——-400.00100.00
Operating Margin-195.45—-195.45-96.00-1,000.00——-800.00-750.00
Net Margin-186.36—-181.82-88.00-966.67——-800.00-750.00
Shares Outstanding3546352725231643
Market Capitalization1471,328483132976755512
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$40.06$29.83$19.60$9.36$-0.87● Close Price0.00M0.84M1.68M2.52M3.35MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 25 '26Option Exercise3.1824,10076,63835,323Jun 29
Krasney KarenEVP, GENERAL COUNSELJun 25 '26Sale30.3824,100732,15830,547Jun 29
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 25 '26Sale30.3824,100732,15811,223Jun 29
Krasney KarenEVP, GENERAL COUNSELJun 25 '26Option Exercise3.1824,10076,63854,647Jun 29
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 24 '26Sale30.0040012,00011,223Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 24 '26Option Exercise3.184001,27211,623Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 24 '26Option Exercise3.184001,27230,947Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 24 '26Sale30.0040012,00030,547Jun 24
Krasney KarenEVP, GENERAL COUNSELJun 22 '26Option Exercise3.185001,59031,047Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERJun 22 '26Option Exercise3.185001,59011,723Jun 24
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 18 '26Option Exercise1.393,0004,17011,223May 19
Litvack FrankDirectorMay 13 '26Option Exercise1.393,9375,472133,776May 14
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 01 '26Option Exercise3.1825,00079,50033,223May 04
Bergmann AnthonyCHIEF FINANCIAL OFFICERMay 01 '26Sale31.7025,000792,5408,223May 04
Krasney KarenEVP, GENERAL COUNSELMay 01 '26Option Exercise3.1825,00079,50055,547May 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.